A Phase I dose-escalation study to determine the maximum tolerated dose of erlotinib when combined with pertuzumab in previously treated non-small-cell lung cancer patients.

E Felip; M Ranson; S CedrÃ©s; E Dean; Droogh E De; M Brewster; V McNally; G Ross; D. Galdermans

A Phase I dose-escalation study to determine the maximum tolerated dose of erlotinib when combined with pertuzumab in previously treated non-small-cell lung cancer patients.

E Felip, M Ranson, S CedrÃ©s, E Dean, Droogh E De, M Brewster, V McNally, G Ross, D. Galdermans

Research output: Contribution to journal › Commentary/debate › peer-review

Original language	English
Pages (from-to)	s89-s124
Journal	Annals of Oncology
Volume	19
Issue number	8s abstr 269P
Publication status	Published - Sept 2008

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{7dbebcb7011142d9bcb4a916200defdb,

title = "A Phase I dose-escalation study to determine the maximum tolerated dose of erlotinib when combined with pertuzumab in previously treated non-small-cell lung cancer patients.",

author = "E Felip and M Ranson and S Cedr{\~A}{\textcopyright}s and E Dean and De, {Droogh E} and M Brewster and V McNally and G Ross and D. Galdermans",

year = "2008",

month = sep,

language = "English",

volume = "19",

pages = "s89--s124",

journal = "Annals of Oncology",

issn = "1569-8041",

publisher = "Elsevier BV",

number = "8s abstr 269P",

}

TY - JOUR

T1 - A Phase I dose-escalation study to determine the maximum tolerated dose of erlotinib when combined with pertuzumab in previously treated non-small-cell lung cancer patients.

AU - Felip, E

AU - Ranson, M

AU - CedrÃ©s, S

AU - Dean, E

AU - De, Droogh E

AU - Brewster, M

AU - McNally, V

AU - Ross, G

AU - Galdermans, D.

PY - 2008/9

Y1 - 2008/9

M3 - Commentary/debate

SN - 1569-8041

VL - 19

SP - s89-s124

JO - Annals of Oncology

JF - Annals of Oncology

IS - 8s abstr 269P

ER -